May 13-17, 2025 | New Orleans, LA | Booth #713
Join Taconic Biosciences at the American Society of Gene and Cell Therapy (ASGCT) 2025
Taconic Biosciences is excited to attend the American Society of Gene and Cell Therapy (ASGCT) 2025! Visit us at booth #713 to connect with our scientific experts and learn how our cutting-edge in vivo models are advancing gene and cell therapy research.
We’ll share new insights through a featured forum presentation and three poster sessions showcasing innovations in mouse model development. Don’t miss the opportunity to engage with our team and discover how Taconic can support your next breakthrough.
We look forward to connecting with the global gene and cell therapy community and contributing to the conversations driving the future of biomedical science.
Key Information:
- When: May 13-17, 2025
- What: One Forum Presentation & Three Poster Presentations: see details below
- Time: See details below
- Where: Booth #713 | New Orleans Ernest N. Morial Convention Center New Orleans, Louisiana
Why Taconic?
Taconic Biosciences is a global leader in genetically engineered mouse models and colony management services. We support researchers in advancing their science with innovative, reliable solutions. Learn More about our Fully Integrated Custom Model Generation and Colony Management Solutions.
Request a Meeting with Taconic at ASGCT
Featured Poster Presentation
Thursday Poster Reception
Thursday, May 15, 2025 | 5:30pm - 7:00pm | Poster Hall I2
Poster #1735: Super Immunodeficient NOG-EXL Mice Have Enhanced Patient-Derived Xenotransplantation of Acute Myeloid Leukemia: An Ideal Model to Test Novel Therapies
Presented by: Laura Griffin, PhD, Taconic Biosciences
University of Pennsylvania in collaboration with Taconic Biosciences
Featured Forum
Tools & Technology Session 5
Friday, May 16, 2025 | 1:45pm - 2:00pm | Exhibit Theater
Forum Title - Strategies for Improved Engraftment and Data Reproducibility in Humanized Immune System (HIS) Mice
Humanized immune system (HIS) mice are valuable tools in advancing our understanding of human disease and preclinical drug development. These models are critical in studying immune-based conditions, including immuno-oncology and autoimmune disorders. Despite their potential, HIS models face challenges, particularly with CD34+ stem cell engraftment, where human donor variability can significantly impact data quality and reproducibility. We explore these hurdles and provide best practices to improve outcomes and solutions supplied by Taconic Biosciences. Key topics include tailored donor selection strategies based on HLA criteria, advanced donor characterization techniques, and flow cytometry solutions from Taconic, all designed to enhance results and reduce costs in the preclinical pipeline.
Humanized immune system (HIS) mice are essential for studying immune-based diseases and drug development. However, CD34+ stem cell engraftment challenges due to donor variability can impact data quality. Taconic Biosciences offers tailored donor selection, advanced characterization, and flow cytometry solutions to enhance outcomes and reduce costs.
Presented by: Laura Griffin, PhD
Poster Presentation
Tuesday Poster Reception
Tuesday, May 13, 2025 | 6:00pm - 7:30pm | Poster Hall I2
Poster #592: Development of a Humanized Immune System Mouse Supporting Primary AML PDX Engraftment for Drug Efficacy Studies
Presented by: Mara Gilardi, PhD, Champions Oncology
Champions Oncology in collaboration with Taconic Biosciences
Poster Presentation
Wednesday Poster Reception
Wednesday, May 14, 2025 | 5:30pm - 7:00pm | Poster Hall I2
Poster #1053: Characterization of a SOD1 Rat Model of ALS using Behavior, Electrophysiology, and Biomarkers: An Ideal Model to Test Novel Gene and Cell Therapies
Presented by: Taleen Hanania, PhD, PsychoGenics
PsychoGenics in collaboration with Taconic Biosciences
Featured Presenter
Laura Griffin, PhD 
Field Applications Scientist
Dr. Laura Griffin has been working with preclinical models for a decade and is experienced in choosing appropriate models for various research applications. She obtained her PhD in Food Science and Technology at Virginia Tech, where she focused on the mechanisms by which dietary bioactive compounds influence the onset of metabolic syndrome using preclinical models. As a postdoctoral fellow at the Plants for Human Health Institute, her research shifted to focus on the impact of the gut microbiome on the metabolism of bioactive compounds. In addition to her expertise in metabolic diseases in preclinical models, Dr. Griffin is also versed in laboratory animal diets and their usage in preclinical applications.
Featured Resources
Connect With an Expert